These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33013255)

  • 1. Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease.
    Balakrishnan V; Lakshminarayanan K
    Int J Pept Res Ther; 2021; 27(1):651-658. PubMed ID: 33013255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computation screening and molecular docking of FDA approved viral protease inhibitors as a potential drug against COVID-19.
    Absalan A; Doroud D; Salehi-Vaziri M; Kaghazian H; Ahmadi N; Zali F; Pouriavali's MH; Mousavi-Nasab SD
    Gastroenterol Hepatol Bed Bench; 2020; 13(4):355-360. PubMed ID: 33244378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
    Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
    Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
    Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
    J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme.
    Bahadur Gurung A; Ajmal Ali M; Lee J; Abul Farah M; Mashay Al-Anazi K
    J King Saud Univ Sci; 2020 Sep; 32(6):2845-2853. PubMed ID: 32837113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.
    Achilonu I; Iwuchukwu EA; Achilonu OJ; Fernandes MA; Sayed Y
    J Mol Graph Model; 2020 Dec; 101():107730. PubMed ID: 32920239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study.
    Hosseini FS; Amanlou M
    Life Sci; 2020 Oct; 258():118205. PubMed ID: 32777300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents.
    Ahmed MZ; Zia Q; Haque A; Alqahtani AS; Almarfadi OM; Banawas S; Alqahtani MS; Ameta KL; Haque S
    J Infect Public Health; 2021 May; 14(5):611-619. PubMed ID: 33866129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy.
    Shamsi A; Mohammad T; Anwar S; AlAjmi MF; Hussain A; Rehman MT; Islam A; Hassan MI
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32441299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of potential drug candidates to combat COVID-19: a structural study using the main protease (mpro) of SARS-CoV-2.
    Sharma P; Vijayan V; Pant P; Sharma M; Vikram N; Kaur P; Singh TP; Sharma S
    J Biomol Struct Dyn; 2021 Oct; 39(17):6649-6659. PubMed ID: 32741313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular docking and simulation studies on SARS-CoV-2 M
    Lokhande KB; Doiphode S; Vyas R; Swamy KV
    J Biomol Struct Dyn; 2021 Nov; 39(18):7294-7305. PubMed ID: 32815481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dynamic simulation study of FDA drug from zinc database against COVID-19 main protease receptor.
    Mathpal S; Joshi T; Sharma P; Joshi T; Pundir H; Pande V; Chandra S
    J Biomol Struct Dyn; 2022 Feb; 40(3):1084-1100. PubMed ID: 32940134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-purposing of hepatitis C virus FDA approved direct acting antivirals as potential SARS-CoV-2 protease inhibitors.
    Uddin R; Jalal K; Khan K; Ul-Haq Z
    J Mol Struct; 2022 Feb; 1250():131920. PubMed ID: 34815586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors.
    Jiménez-Alberto A; Ribas-Aparicio RM; Aparicio-Ozores G; Castelán-Vega JA
    Comput Biol Chem; 2020 Oct; 88():107325. PubMed ID: 32623357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
    Park SJ; Yu KM; Kim YI; Kim SM; Kim EH; Kim SG; Kim EJ; Casel MAB; Rollon R; Jang SG; Lee MH; Chang JH; Song MS; Jeong HW; Choi Y; Chen W; Shin WJ; Jung JU; Choi YK
    mBio; 2020 May; 11(3):. PubMed ID: 32444382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors.
    Kalhotra P; Chittepu VCSR; Osorio-Revilla G; Gallardo-Velazquez T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33578831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide-like and small-molecule inhibitors against Covid-19.
    Pant S; Singh M; Ravichandiran V; Murty USN; Srivastava HK
    J Biomol Struct Dyn; 2021 May; 39(8):2904-2913. PubMed ID: 32306822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.